Press Releases

Aug 18, 2021

Jnana Therapeutics closes $50 million Series B financing to advance lead PKU program and small molecule pipeline based on next gen chemoproteomic platform

– Funds progression of lead program, an oral approach to treating phenylketonuria (PKU), into the clinic – – Supports expanded application of chemoproteomic RAPID platform for small-molecule discovery for hard-to-drug targets – Boston, Mass., August, 18, 2021 – Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other […]

Read More >

Feb 3, 2021

Jnana Therapeutics Expands Leadership Team with Two Experienced Biopharmaceutical Executives

Company appoints Nick Pullen, PhD, as Senior VP, Head of Biology and Brian Danieli as VP, Head of Finance & Operations  Boston, Mass. – February 3, 2021 – Jnana Therapeutics, a biotechnology company targeting the solute carrier (SLC) family of metabolite transporters to treat underserved diseases, today announced that it has expanded its leadership team […]

Read More >

Jan 6, 2021

Jnana Therapeutics Appoints Dr. Annie Chen to Board of Directors and Dr. Katalin Susztak to Scientific Advisory Board

Veteran leaders bring deep scientific and clinical expertise as Jnana advances its pipeline toward the clinic Boston, Mass. – January 6, 2021 – Jnana Therapeutics, a biotechnology company targeting the solute carrier (SLC) family of metabolite transporters to treat underserved diseases, today announced the appointment of two experienced scientific and clinical leaders to the company’s […]

Read More >

Jul 21, 2020

Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism to Treat Immune-Mediated and Neurological Diseases

Jnana to receive $40 million upfront and is eligible to receive milestone payments with potential for future payments exceeding $1 billion Boston, MA – July 21, 2020 – Jnana Therapeutics today announced a strategic, multi-target collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery of small molecule drugs directed at […]

Read More >

Oct 1, 2019

Jnana Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

Boston, Mass., October 1, 2019 – Jnana Therapeutics, a biotechnology company targeting the solute carrier (SLC) family of metabolite transporters to treat underserved diseases, today announced the appointment of Caroline Stark Beer as its chief business officer. Ms. Stark Beer joins Jnana after over a decade at Alnylam Pharmaceuticals, where she served in a variety of […]

Read More >

Apr 5, 2019

Jnana Therapeutics Appoints Donald Nicholson, Ph.D., as Chair of its Board of Directors

Boston, Mass., April 5, 2019 – Jnana Therapeutics today announced the appointment of Donald Nicholson, Ph.D., an accomplished scientist and executive, as chair of its Board of Directors. Don most recently served as chief executive officer of Nimbus Therapeutics. “I am thrilled to welcome Don as chair of our Board of Directors. Don’s experience and […]

Read More >

Dec 20, 2018

Jnana Therapeutics Expands Board of Directors and Forms Scientific Advisory Board

Stuart Schreiber, Ph.D. and Brian Cali, Ph.D. appointed to Board Inaugural SAB comprises renowned leaders in the investigation of disease biology and applications to drug discovery and development Boston, Mass. – Dec. 20, 2018 – Jnana Therapeutics today announced the appointment of two new members to its Board of Directors: Stuart Schreiber, Ph.D., a co-founder […]

Read More >

Nov 6, 2018

Jnana Therapeutics Announces Appointment Of Joanne Kotz, Ph.D. As Chief Executive Officer

Boston Mass. – Nov. 6, 2018 – Jnana Therapeutics today announced that Joanne Kotz, Ph.D., a company co-founder, has been named Chief Executive Officer. Dr. Kotz has served as Jnana’s president since December 2017. “Joanne has demonstrated exceptional leadership in guiding the company through its early stages of growth, and we believe she is the […]

Read More >

Oct 9, 2018

Neurocrine Biosciences And Jnana Therapeutics Enter Strategic Collaboration To Discover Novel Medicines To Treat Central Nervous System Disorders

Partnership Leverages Neurocrine’s Expertise in Neuroscience and Jnana’s Proprietary Drug Discovery Platform Targeting the Solute Carrier Family of Transporters SAN DIEGO and BOSTON, Oct. 9, 2018 – Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at discovering novel small molecule therapeutics for multiple […]

Read More >

Oct 2, 2018

FierceBiotech Names Jnana Therapeutics As One Of Its “Fierce 15” Biotech Companies Of 2018

Boston, Mass. – October 2, 2018 – Jnana Therapeutics today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Jnana Therapeutics was launched in 2017 to build the first drug discovery platform targeting the […]

Read More >


Oct 12, 2020

Fragment-based screening sees the light

Nature Reviews Drug Discovery, October 2020

Jul 22, 2020

Roche, Jnana sign multi-target collaboration deal for small molecule drugs

Pharmaceutical Business Review

Jul 21, 2020

Roche, Jnana Enter Drug R&D Alliance Targeting Metabolism’s Gatekeepers


Jul 21, 2020

Roche, Jnana take aim at metabolite transporters in $40M discovery deal

Fierce Biotech

Apr 16, 2020

Scripps Research expands international effort to rapidly repurpose existing drugs against COVID-19

Scripps Research, April 2020

Oct 14, 2018

Jnana Therapeutics tries to take on an untapped class of proteins

Chemical and Engineering News, October 2018

The Gateway Forum

Aug 17, 2020

Building an SLC Drug Discovery Platform: Opening the Gates to a Pipeline of New Transporter Drugs

2020 Fall ACS Meeting - Joel Barrish (CSO)

View Presentation >

Jul 21, 2020

Right time, right team to open up an emerging class of drug targets

By Joanne Kotz (CEO) and Joel Barrish (CSO)

Read More >


Back to Top

This links to an external website. Merus is not responsible for any third party content.